IL308296A - שימוש בנוגדן אנטי- cd19לטיפול במיאסטניה גראביס - Google Patents

שימוש בנוגדן אנטי- cd19לטיפול במיאסטניה גראביס

Info

Publication number
IL308296A
IL308296A IL308296A IL30829623A IL308296A IL 308296 A IL308296 A IL 308296A IL 308296 A IL308296 A IL 308296A IL 30829623 A IL30829623 A IL 30829623A IL 308296 A IL308296 A IL 308296A
Authority
IL
Israel
Prior art keywords
antibody
myasthenia gravis
treat myasthenia
treat
gravis
Prior art date
Application number
IL308296A
Other languages
English (en)
Inventor
Eliezer Katz
John N Ratchford
Liron Abuhsira
Original Assignee
Viela Bio Inc
Eliezer Katz
John N Ratchford
Liron Abuhsira
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc, Eliezer Katz, John N Ratchford, Liron Abuhsira filed Critical Viela Bio Inc
Publication of IL308296A publication Critical patent/IL308296A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL308296A 2021-05-07 2022-05-06 שימוש בנוגדן אנטי- cd19לטיפול במיאסטניה גראביס IL308296A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163185613P 2021-05-07 2021-05-07
US202263303655P 2022-01-27 2022-01-27
PCT/US2022/028063 WO2022236047A1 (en) 2021-05-07 2022-05-06 Use of an anti-cd19 antibody to treat myasthenia gravis

Publications (1)

Publication Number Publication Date
IL308296A true IL308296A (he) 2024-01-01

Family

ID=81846343

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308296A IL308296A (he) 2021-05-07 2022-05-06 שימוש בנוגדן אנטי- cd19לטיפול במיאסטניה גראביס

Country Status (10)

Country Link
US (1) US20240270842A1 (he)
EP (1) EP4333987A1 (he)
JP (1) JP2024518410A (he)
KR (1) KR20240004367A (he)
AU (1) AU2022270697A1 (he)
BR (1) BR112023022133A2 (he)
CA (1) CA3217586A1 (he)
IL (1) IL308296A (he)
MX (1) MX2023012703A (he)
WO (1) WO2022236047A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024155810A1 (en) * 2023-01-20 2024-07-25 Viela Bio, Inc. Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
EA010594B1 (ru) 2001-05-24 2008-10-30 Займодженетикс, Инк. Слитые белки taci-иммуноглобулина
KR20110017020A (ko) 2002-10-17 2011-02-18 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
PT2272868E (pt) 2003-06-05 2015-07-07 Genentech Inc Terapêutica de combinação para distúrbios de células b
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
JP5401314B2 (ja) 2006-09-08 2014-01-29 メディミューン,エルエルシー ヒト化抗cd19抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
WO2009052431A2 (en) * 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
JP2012518404A (ja) * 2009-02-23 2012-08-16 グレンマーク・ファーマシューティカルズ・エスエー Cd19に結合するヒト化抗体及びその使用
EP3157553A4 (en) 2014-06-16 2018-02-28 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
JP2019515874A (ja) 2016-03-01 2019-06-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 改変された細胞死誘導を有するオビヌツズマブ変異体
CN113939532A (zh) * 2019-04-24 2022-01-14 维埃拉生物股份有限公司 使用抗cd19抗体治疗自身免疫性疾病

Also Published As

Publication number Publication date
JP2024518410A (ja) 2024-05-01
EP4333987A1 (en) 2024-03-13
US20240270842A1 (en) 2024-08-15
WO2022236047A9 (en) 2023-09-21
BR112023022133A2 (pt) 2023-12-26
MX2023012703A (es) 2023-11-21
KR20240004367A (ko) 2024-01-11
AU2022270697A1 (en) 2023-10-19
WO2022236047A1 (en) 2022-11-10
CA3217586A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
SG11202112951TA (en) Detection of antibodies to sarsr-cov
IL274603A (he) שימוש באנטגוניסטים fcrn לטיפול במיאסטניה גרביס
IL289561A (he) הערכת נפח ריאות באמצעות אנליזת דיבור
IL277735A (he) קולטנים כימריים של dll3 ושיטות שימוש בהם
CL2018000728A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
GB201802236D0 (en) purification of hydrocarbons
GB2519392B (en) Auto-tuning of an acoustic echo canceller
IL241261B (he) טיפול בסרטן תוך שימוש ברצפטור אנושי אנטיגן כימרי נוגד cd19
PL3831162T3 (pl) Optymalizacja płaszczyzny użytkownika dla komórkowego internetu rzeczy 5g
EP3638696B8 (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
SG11202103801UA (en) Method for the treatment of myasthenia gravis
IL287385A (he) שימוש בנוגדן אנטי-cd19 לטיפול במחלה אוטואימונית
GB202012434D0 (en) Multiomic analysis of nanoparticle-coronas
AU2022270697A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
SG11202010324TA (en) Formulations of human anti-pd-l1 antibodies
CA200172S (en) Part of luggage
IL267273A (he) ניתוח קול לקביעת מקורות הקול ובידודם
HK40102276A (en) Use of an anti-cd19 antibody to treat myasthenia gravis
SG11202011832WA (en) Method for capacitive cancellation of tuning fork for fluid property measurements
IL299110A (he) שיטות לקביעת היענות לאימונותרפיה לסרטן
HK40061235A (en) Use of an anti-cd19 antibody to treat autoimmune disease
IL310409B2 (he) ניקוי נוגדנים בהיקף גבוה
GB202108596D0 (en) Methods of selectively reducing antibodies
SG11202011717UA (en) Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies
IL308603A (he) שימושים בנוגדנים כנגד icos